Clinical Trial Update: The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of neprilysin inhibitor LCZ696 (sacubitril/valsartan) on exercise tolerance in patients with heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: University of Sao Paulo General Hospital | Conditions: Heart Failure, Exercise Tolerance | Phase 4 | Status: COMPLETED